AstraZeneca Pharma India cash flow

Latest FY26

Cash from operations: −₹15.1cr₹65.4 cr in FY25
Capital spending: ₹3.6cr+106.3% on FY25
Free cash flow: −₹18.8cr₹63.6 cr in FY25
Cash from financing: −₹92.0cr−₹65.6 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	28.6	40.0	14.9	16.3
	—	0.0	0.5	0.0	0.0
	—	4.5	1.5	1.2	0.6
	—	0.0	−31.6	0.0	−23.1
	—	1.1	5.1	2.7	2.4
	—	−1.0	−0.7	0.2	−0.1
	—	23.8	62.0	6.5	−0.8
	—	0.0	−0.3	0.0	0.0
	—	−479	−321	−37.7	−50.0
	—	−45.8	−31.7	−51.2	−23.2
	—	0.0	−5.3	−4.4	1.6
	—	−1.4	0.0	−1.2	−0.6
	—	22.4	−28.3	−1.2	−7.9
	—	0.0	0.0	0.0	−0.0
	—	326	260	−31.4	37.4
	—	−4.2	−6.8	−1.6	−13.9
	—	0.0	0.0	−0.4	−1.3
	—	16.0	29.3	0.0	31.5
	—	−52.3	0.3	0.9	−4.8
	—	0.0	0.0	0.0	1.1
Cash from operating activities
	228	252	156	220	134
	—	−161	−26.8	−103	−35.0
	—	91.4	130	117	99.1
	—	−23.2	0.0	32.1	0.0
	—	83.3	64.2	56.4	40.8
	—	−15.1	65.4	92.5	58.3
Cash from investing activities
	—	3.6	1.8	10.8	8.5
	—	0.3	0.7	0.4	0.0
	—	0.0	0.0	0.0	3.5
	—	22.0	31.8	32.1	23.1
	—	18.7	30.8	21.7	18.1
Cash from financing activities
	—	7.5	5.5	0.0	3.9
	—	—	—	3.9	0.6
	—	4.5	0.1	0.5	0.0
	—	80.0	60.0	40.0	20.0
	—	−92.0	−65.6	−44.4	−24.5
	—	−88.4	30.6	69.9	51.9
	—	−88.4	30.6	69.9	51.9
	—	—	—	69.9	51.9
Reference items
	230	262	254	184	165
	9.5%	11.5%	14.8%	14.2%	16.5%
	−18.8	−18.8	63.6	81.8	49.8
	—	−23.2	63.6	81.2	—
	−₹7.50	−₹7.50	₹25.44	₹32.71	₹19.91
	—	−0.08×	0.56×	0.57×	0.59×
	—	83.3	64.2	56.4	40.8
	—	4.5	0.1	0.5	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

ASTRAZEN₹6,237.00

AstraZeneca Pharma India Limited

· Pharma & Health

₹ CrorePeersSANOFICONR PGHL SANOFI SENORES INNOVACAP MOREPENLAB IOLCP FDCMcap ₹15,593 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	16.3	14.9	40.0	28.6	—
+ Impairment Loss / (Reversal)	0.0	0.0	0.5	0.0	—
+ Finance Costs	0.6	1.2	1.5	4.5	—
+ Interest Income	-23.1	0.0	-31.6	0.0	—
+ Share-based Payments	2.4	2.7	5.1	1.1	—
+ Unrealised FX (Gain) / Loss	-0.1	0.2	-0.7	-1.0	—
+ Other Non-cash Items	-0.8	6.5	62.0	23.8	—
+ Other — Cash Effects are Investing / Financing	0.0	0.0	-0.3	0.0	—
Changes in Working Capital
+ Inventories	-50.0	-37.7	-320.6	-478.8	—
+ Trade Receivables — Current	-23.2	-51.2	-31.7	-45.8	—
+ Other Financial Assets — Current	1.6	-4.4	-5.3	0.0	—
+ Other Financial Assets — Non-current	-0.6	-1.2	0.0	-1.4	—
+ Other Current Assets	-7.9	-1.2	-28.3	22.4	—
+ Other Non-current Assets	-0.0	0.0	0.0	0.0	—
+ Trade Payables — Current	37.4	-31.4	259.8	326.4	—
+ Other Financial Liabilities — Current	-13.9	-1.6	-6.8	-4.2	—
+ Other Financial Liabilities — Non-current	-1.3	-0.4	0.0	0.0	—
+ Other Current Liabilities	31.5	0.0	29.3	16.0	—
+ Provisions — Current	-4.8	0.9	0.3	-52.3	—
+ Provisions — Non-current	1.1	0.0	0.0	0.0	—
Cash from Operating Activities
Profit Before Tax (per I/S)	134.1	219.5	156.4	252.2	228.3
+ Total Adjustments (incl. Working Capital)	-35.0	-102.7	-26.8	-160.8	—
Cash from Operations (pre-tax)	99.1	116.9	129.6	91.4	—
+ Interest Received — Operating	0.0	32.1	0.0	-23.2	—
+ Income Taxes Paid	40.8	56.4	64.2	83.3	—
Cash from Operating Activities	58.3	92.5	65.4	-15.1	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	8.5	10.8	1.8	3.6	—
+ Disp of Fixed Assets	0.0	0.4	0.7	0.3	—
+ Disp of Investment Property	3.5	0.0	0.0	0.0	—
+ Interest Received — Investing	23.1	32.1	31.8	22.0	—
Cash from Investing Activities	18.1	21.7	30.8	18.7	—
Cash from Financing Activities
+ Payment of Lease Liabilities	3.9	0.0	5.5	7.5	—
+ Payment of Finance Lease Liabilities	0.6	3.9	—	—	—
+ Interest Paid	0.0	0.5	0.1	4.5	—
+ Dividends Paid	20.0	40.0	60.0	80.0	—
Cash from Financing Activities	-24.5	-44.4	-65.6	-92.0	—
Net Changes in Cash (pre-FX)	51.9	69.9	30.6	-88.4	—
Net Changes in Cash	51.9	69.9	30.6	-88.4	—
Closing Cash	51.9	69.9	—	—	—
Reference Items
EBITDA	165.1	184.4	254.0	262.0	229.9
EBITDA Margin %	16.46	14.24	14.80	11.51	9.45
Free Cash Flow (CFO − Capex)	49.8	81.8	63.6	-18.8	-18.8
Free Cash Flow to Equity	—	81.2	63.6	-23.2	—
Free Cash Flow per Basic Share	19.91	32.71	25.44	-7.50	-7.50
Cash Flow to Net Income	0.59	0.57	0.56	-0.08	—
Cash Paid for Taxes	40.8	56.4	64.2	83.3	—
Cash Paid for Interest	—	0.5	0.1	4.5	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.